Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Yaël C. Cohen, Hila Magen, Noa Lavi, Moshe E. Gatt, Evgeni Chubar, Nethanel A. Horowitz, Natalia Kreiniz, Tamar Tadmor, Svetlana Trestman, Roy Vitkon, Ory Rouvio, Olga Shvetz, Adir Shaulov, Tomer Ziv‐Baran, Irit Avivi
Topics & Concepts
IxazomibLenalidomideMedicineInternal medicineTolerabilityMultiple myelomaClinical endpointOncologyPomalidomideCarfilzomibInterim analysisClinical trialSurgeryAdverse effectMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsUbiquitin and proteasome pathways